Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
Provided By GlobeNewswire
Last update: Jan 27, 2025
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® -
Read more at globenewswire.com5.01
+0.2 (+4.16%)
NASDAQ:DRTSW (12/18/2025, 8:20:08 PM)
0.33
-0.02 (-6.86%)
Find more stocks in the Stock Screener
DRTS Latest News and Analysis
